• Crizotinib Hydrochloride in Patient-Derived Tumor Assembl...

  2025-10-19

  Crizotinib hydrochloride, an ATP-competitive inhibitor targeting ALK, c-Met, and ROS1 kinases, is transforming cancer research by enabling unprecedented mechanistic insight into oncogenic signaling within physiologically relevant tumor microenvironments. This thought-leadership article integrates the latest advances in patient-derived gastric cancer assembloid models, critically reviews experimental paradigms, and provides strategic guidance for translational researchers seeking to unravel drug resistance and optimize precision oncology. By bridging the gap between molecular mechanism and translational application, we position Crizotinib hydrochloride as an indispensable tool for next-generation cancer biology studies.

• Crizotinib Hydrochloride in Advanced Tumor Assembloid Mod...

  2025-10-18

  Translational oncology is undergoing a paradigm shift, driven by intricate tumor models and precision-targeted inhibitors. This thought-leadership article explores how Crizotinib hydrochloride—an ATP-competitive inhibitor of ALK, c-Met, and ROS1 kinases—is empowering researchers to dissect oncogenic signaling and drug resistance in patient-derived assembloid models. By synthesizing mechanistic insight and strategic guidance, the article charts a visionary path for translational scientists seeking breakthroughs beyond traditional cancer research approaches.

2 records 1/1 page